TC 6499

Drug Profile

TC 6499

Alternative Names: TC-6499; TC-6499-12

Latest Information Update: 20 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targacept
  • Developer GlaxoSmithKline; Targacept
  • Class Irritable bowel syndrome therapies; Non-opioid analgesics; Small molecules
  • Mechanism of Action Alpha3beta4 nicotinic receptor agonists; Alpha4beta2 nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic gastroparesis; Irritable bowel syndrome; Neuropathic pain

Most Recent Events

  • 18 Oct 2016 Catalyst Biosciences enters into a definitive agreement with an undisclosed partner for the divestiture of its neuronal nicotinic receptor, TC 6499
  • 16 Apr 2015 Discontinued - Phase-I/II for Diabetic gastroparesis in USA (PO)
  • 16 Apr 2015 Targacept completes a phase I/II trial for Diabetic gastroparesis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top